These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 28415009)

  • 21. Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
    Xie R; Li Y; Tang P; Yuan Q
    Eur J Med Chem; 2018 Jan; 143():320-333. PubMed ID: 29202397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HDAC3 is a potential validated target for cancer: An overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches.
    Adhikari N; Amin SA; Trivedi P; Jha T; Ghosh B
    Eur J Med Chem; 2018 Sep; 157():1127-1142. PubMed ID: 30179749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
    Lee HY; Wang LT; Li YH; Pan SL; Chen YL; Teng CM; Liou JP
    Org Biomol Chem; 2014 Nov; 12(44):8966-76. PubMed ID: 25277250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.
    Marson CM; Matthews CJ; Atkinson SJ; Lamadema N; Thomas NS
    J Med Chem; 2015 Sep; 58(17):6803-18. PubMed ID: 26287310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.
    Mehndiratta S; Wang RS; Huang HL; Su CJ; Hsu CM; Wu YW; Pan SL; Liou JP
    Eur J Med Chem; 2017 Jul; 134():13-23. PubMed ID: 28395150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of potent, isoform-selective inhibitors of histone deacetylase containing chiral heterocyclic capping groups and a N-(2-aminophenyl)benzamide binding unit.
    Marson CM; Matthews CJ; Yiannaki E; Atkinson SJ; Soden PE; Shukla L; Lamadema N; Thomas NS
    J Med Chem; 2013 Aug; 56(15):6156-74. PubMed ID: 23829483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HDAC1/3 dual selective inhibitors - new therapeutic agents for the potential treatment of cancer.
    Li X; Xu W
    Drug Discov Ther; 2014 Oct; 8(5):225-8. PubMed ID: 25382558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
    Liu YM; Lee HY; Lai MJ; Pan SL; Huang HL; Kuo FC; Chen MC; Liou JP
    Org Biomol Chem; 2015 Oct; 13(40):10226-35. PubMed ID: 26309122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure optimization and preliminary bioactivity evaluation of N-hydroxybenzamide-based HDAC inhibitors with Y-shaped cap.
    Yu C; He F; Qu Y; Zhang Q; Lv J; Zhang X; Xu A; Miao P; Wu J
    Bioorg Med Chem; 2018 May; 26(8):1859-1868. PubMed ID: 29500131
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Gerokonstantis DT; Mantzourani C; Gkikas D; Wu KC; Hoang HN; Triandafillidi I; Barbayianni I; Kanellopoulou P; Kokotos AC; Moutevelis-Minakakis P; Aidinis V; Politis PK; Fairlie DP; Kokotos G
    J Med Chem; 2023 Oct; 66(20):14357-14376. PubMed ID: 37795958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.
    Yun F; Cheng C; Ullah S; He J; Zahi MR; Yuan Q
    Eur J Med Chem; 2019 Aug; 176():195-207. PubMed ID: 31103900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of adamantane based highly potent HDAC inhibitors.
    Gopalan B; Ponpandian T; Kachhadia V; Bharathimohan K; Vignesh R; Sivasudar V; Narayanan S; Mandar B; Praveen R; Saranya N; Rajagopal S; Rajagopal S
    Bioorg Med Chem Lett; 2013 May; 23(9):2532-7. PubMed ID: 23538115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3D-QSAR (CoMFA, CoMSIA) and Molecular Docking Studies on Histone Deacetylase 1 Selective Inhibitors.
    Abdizadeh T; Ghodsi R; Hadizadeh F
    Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):365-383. PubMed ID: 28482791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of N-hydroxycinnamamide-based HDAC inhibitors with improved HDAC inhibitory activity and in vitro antitumor activity.
    Zang J; Shi B; Liang X; Gao Q; Xu W; Zhang Y
    Bioorg Med Chem; 2017 May; 25(9):2666-2675. PubMed ID: 28336407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents.
    Cai J; Wei H; Hong KH; Wu X; Zong X; Cao M; Wang P; Li L; Sun C; Chen B; Zhou G; Chen J; Ji M
    Bioorg Med Chem; 2015 Jul; 23(13):3457-71. PubMed ID: 25953722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.
    Yang Z; Wang T; Wang F; Niu T; Liu Z; Chen X; Long C; Tang M; Cao D; Wang X; Xiang W; Yi Y; Ma L; You J; Chen L
    J Med Chem; 2016 Feb; 59(4):1455-70. PubMed ID: 26443078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors.
    Jiao J; Fang H; Wang X; Guan P; Yuan Y; Xu W
    Eur J Med Chem; 2009 Nov; 44(11):4470-6. PubMed ID: 19608304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
    Abdizadeh T; Kalani MR; Abnous K; Tayarani-Najaran Z; Khashyarmanesh BZ; Abdizadeh R; Ghodsi R; Hadizadeh F
    Eur J Med Chem; 2017 May; 132():42-62. PubMed ID: 28340413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors.
    Yamashita M; Tahara T; Hayakawa S; Matsumoto H; Wada SI; Tomioka K; Iida A
    Bioorg Med Chem; 2018 May; 26(8):1920-1928. PubMed ID: 29519604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
    Liao V; Liu T; Codd R
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.